- Home
- KNOP vs SLN Comparison
KNOP vs SLN Comparison
Compare KNOP & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- SLN
- Stock Information
- Founded
- KNOP 2013
- SLN 1994
- Country
- KNOP United Kingdom
- SLN United Kingdom
- Employees
- KNOP 874
- SLN N/A
- Industry
- KNOP Marine Transportation
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- KNOP Consumer Discretionary
- SLN Health Care
- Exchange
- KNOP Nasdaq
- SLN Nasdaq
- Market Cap
- KNOP 243.2M
- SLN 273.9M
- IPO Year
- KNOP 2013
- SLN N/A
- Fundamental
- Price
- KNOP $6.97
- SLN $6.47
- Analyst Decision
- KNOP
- SLN Buy
- Analyst Count
- KNOP 0
- SLN 5
- Target Price
- KNOP N/A
- SLN $32.60
- AVG Volume (30 Days)
- KNOP 61.1K
- SLN 107.6K
- Earning Date
- KNOP 09-02-2025
- SLN 08-14-2025
- Dividend Yield
- KNOP 1.48%
- SLN N/A
- EPS Growth
- KNOP N/A
- SLN N/A
- EPS
- KNOP 0.19
- SLN N/A
- Revenue
- KNOP $320,026,000.00
- SLN $27,701,000.00
- Revenue This Year
- KNOP $9.28
- SLN N/A
- Revenue Next Year
- KNOP N/A
- SLN N/A
- P/E Ratio
- KNOP $36.54
- SLN N/A
- Revenue Growth
- KNOP 8.76
- SLN N/A
- 52 Week Low
- KNOP $5.28
- SLN $1.97
- 52 Week High
- KNOP $8.15
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- KNOP 60.20
- SLN 64.49
- Support Level
- KNOP $6.29
- SLN $5.33
- Resistance Level
- KNOP $7.21
- SLN $6.55
- Average True Range (ATR)
- KNOP 0.24
- SLN 0.44
- MACD
- KNOP 0.05
- SLN 0.02
- Stochastic Oscillator
- KNOP 77.14
- SLN 89.34
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.